Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study

Clinical Therapeutics

Volumn 26, Issue 2, 2004, Pages 245-256

  Turbí, Carmen ^a,g   Herrero Beaumont, Gabriel ^b   Acebes, Juan Carlos ^b   Torrijos, Antonio ^c   Graña, Jenaro ^d   Miguélez, Roberto ^e   Sacristán, José Antonio ^a   Marín, Fernando ^f  

^a Department of Medical Research   (Spain)

^b Rheumatology Service   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL DE MÓSTOLES   (Spain)

^f ELI LILLY AND COMPANY   (United States)

^g NONE   (Spain)

Author keywords

Alendronate; Clinical practice; Compliance; Osteoporosis; Postmenopausal; Raloxifene

Indexed keywords

ALENDRONIC ACID; RALOXIFENE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATION; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE OSTEOPOROSIS; QUESTIONNAIRE; SIDE EFFECT; SPAIN; STOMACH PAIN; THROMBOEMBOLISM;

EID: 1542406574     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90023-9     Document Type: Article

References (30)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348: 1535-1541.
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998;280: 2077-2082.
3. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [published correction appears in JAMA. 1999;282:2124]. JAMA. 1999;282:637-645.
4. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
5. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions and discontinuation. J Manag Care Pharm. 1998;4: 488-492.
6. Ettinger B, Tosteson AN, Grove M, et al. Side effect severity and discontinuation rate among women initiating hormone replacement therapy raloxifene, or alendronate following BMD testing. Bone. 2001;28:S76.
7. Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: Discontinuation of raloxifene versus estrogen. Menopause. 2001;8:328-332.
8. Fawcett J. Compliance: Definitions and key issues. J Clin Psychiatry. 1995;56(Suppl 1):4-8.
9. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115:209-216.
10. Raloxifene Hydrochloride (Evista®). Summary of product characteristics. Madrid, Spain: Eli Lilly and Company; 2000.
11. Alendronate Sodium (Fosamax®). Summary of product characteristics. Madrid, Spain: Merck, Sharp & Dohme; 2000.
12. Batalla C, Blanquer A, Ciurana R, et al. Compliance with drug therapy in hypertensive patients [in Spanish]. Aten Primaria. 1984;1:185-191.
13. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
14. Val Jimenez A, Amoros Ballestero G, Martinez Visa P, et al. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test [in Spanish]. Aten Primaria. 1992;10:767-770.
15. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet. 1976;1:1265-1268.
16. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43-49.
17. Sclar DA. Improving medication compliance: A review of selected issues. Clin Ther. 1991;13:436-440.
18. Ettinger B, Shein JR, Pressman A. Upper gastrointestinal symptoms and noncompliance with dosing instructions associated with alendronate for osteoporosis in a large HMO. Bone. 1998;23:S311.
19. Nattrass S, Silverman S, Drinkwater B. Effectiveness of education and/or NTx results as a means of encouraging compliance to alendronate. Osteoporos Int. 2000;11:S164.
20. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090.
21. McCombs JS, Cody M, Besinque K, et al. Measuring the impact of patient counseling in the outpatient pharmacy setting: The research design of the Kaiser Permanente/USC patient consultation study. Clin Ther. 1995;17:1188-1206.
22. Melnikow J, Kiefe C. Patient compliance and medical research: Issues in methodology. J Gen Intern Med. 1994;9:96-105.
23. Gil V, Pineda M, Martínez JL, et al. Validity of 6 indirect methods to assess treatment compliance in arterial hypertension [in Spanish]. Med Care (Barc). 1994;102:532-536.
24. George CF, Peveler RC, Heiliger S, Thompson C. Compliance with tricyclic antidepressants: The value of four different methods of assessment. Br J Clin Pharmacol. 2000;50:166-171.
25. Gao X, Nau DP. Congruence of three self-report measures of medication adherence among HIV patients. Ann Pharmacother. 2000;34:1117-1122.
26. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189-1197.
27. Faulkner DL, Lucy LM, Heath H, et al. A claims data assessment of patient compliance with alendronate. Osteoporos Int. 1998;8(Suppl 3):21.
28. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 1998;4:1377-1382.
29. Kelly R, Taggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ. 1997;315:1235.
30. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-262.